Loading…
DYN
Dyne Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 26818M108
$15.77-1.87%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Dyne Therapeutics, Inc. (DYN) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Waltham, United States and has 289 employees. The company is worth $2.94B. The share price is 42.2% below its 52-week high of $27.31. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $25.41M. In that quarter, 2 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders bought $40K of its stock on the open market and sold none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $2.94B
- P/E
- —
- Forward P/E
- —
- P/B
- 3.7x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$3.24
- ROE
- -81.56%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.12
- 52-week high
- $27.31
- 52-week low
- $14.00
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Ken GriffinAddedCitadel Advisors · Q2 2026$25.41M1.14M shares · 0.0% of portfolio- Israel EnglanderAddedMillennium Management · Q2 2026$9.59M431.85K shares · 0.0% of portfolio
- Renaissance TechnologiesReducedRenaissance Technologies · Q2 2026$8.01M360.57K shares · 0.0% of portfolio
- Cliff AsnessHeldAQR Capital Management · Q2 2026$1.87M84.05K shares · 0.0% of portfolio
- Two SigmaHeldTwo Sigma Investments · Q2 2026$314.89K14.18K shares · 0.0% of portfolio
Price over time
▲ +0.3% over 5Y.
today you would have $982.08▼ -1.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $19.56 | $23.56 | $13.30 | $11.59 | $11.89 | $21.00 | |
| P/B | 3.2x | 3.3x | 4.2x | 11.9x | 2.6x | 1.7x | 3.2x |
| EPS | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | |
| ROE | -48.15% | -45.90% | -50.40% | -258.44% | -66.61% | -40.55% | -17.36% |
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PRVAPrivia Health Group, Inc. | $22.89 | 109.0x | 3.7x | 0.00% | 4.31% | $2.92B |
| ACHCAcadia Healthcare Company, Inc. | $31.88 | — | 1.5x | 0.00% | -41.45% | $2.97B |
| DNLIDenali Therapeutics Inc. | $18.66 | — | 3.6x | 0.00% | -54.93% | $2.98B |
| IRONDisc Medicine, Inc. | $75.03 | — | 4.5x | 0.00% | -39.08% | $2.88B |
| ATRCAtriCure, Inc. | $59.30 | 282.4x | 5.8x | 0.00% | 2.15% | $3.02B |
| ELVNEnliven Therapeutics, Inc. | $41.93 | — | 3.4x | 0.00% | -15.31% | $3.07B |
About the company
- 289
- Waltham, United States